论文部分内容阅读
1978年2月,福州市医科所根据祖国医学有关蟑螂抗肿瘤的记载,对“AT-2”制剂的抗癌作用进行了初步研究。同年8月,由十四个单位组成协作组,进一步进行系统的观察。用蟑螂及其提取物进行了急、慢性毒性试验及临床观察,对心、肝、肾未发现明显毒性作用。用蟑螂不同溶剂提取物对小鼠S_(180)的抑瘤试验,其抑瘤率为35～56％,试验证明它对EAC的癌细胞有直接的杀灭作用。 1978年3月至1981年5月,我们用蟑螂浸膏片或蟑螂粉胶囊共治疗37例中、晚期原发性肝癌。疗效评定按1978年全国抗肿瘤药物会议拟定的标准,单用“AT-2”33例中,稳定者22例,进展者11例,有效率为66.67％。随访30例,其中22例已死亡,8例仍存活。30例病后、治后平均生存期分别为8.25个
In February 1978, Fuzhou Medical Research Institute conducted a preliminary study on the anti-cancer effects of the “AT-2” preparation based on records of the anti-cancer drugs of the motherland. In August of the same year, a collaborative group of 14 units was formed to further observe the system. Acute and chronic toxicity tests and clinical observations were performed using wolfberry and its extracts. No obvious toxic effects were found on hearts, livers, and kidneys. The inhibitory effect of different solvent extracts on the S180 mouse tumor was 35 to 56%. The test proved that it had a direct killing effect on EAC cancer cells. From March 1978 to May 1981, we treated 37 cases of primary and advanced primary liver cancer with wolfberry extract or wolfberry powder capsules. Efficacy assessment According to the standard formulated by the national anticancer drug conference in 1978, only 33 cases of “AT-2” were used, of which 22 were stable and 11 were progressive, and the effective rate was 66.67%. Thirty patients were followed up, of which 22 were dead and 8 were still alive. The average survival time of 30 patients after illness and after treatment was 8.25